Oritinib
A tyrosine kinase inhibitor used in cancer treatment
Oritinib is a tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain types of cancer. It functions by inhibiting the activity of specific enzymes known as tyrosine kinases, which play a crucial role in the signaling pathways that regulate cell division and survival. By blocking these enzymes, oritinib can help to slow down or stop the growth of cancer cells.
Mechanism of Action[edit | edit source]
Oritinib targets the epidermal growth factor receptor (EGFR), a protein that is often overexpressed or mutated in various cancers. EGFR is a receptor tyrosine kinase that, when activated, triggers a cascade of downstream signaling pathways that promote cell proliferation and survival. Oritinib binds to the ATP-binding site of the EGFR, preventing its activation and subsequent signaling. This inhibition can lead to reduced tumor growth and increased cancer cell death.
Clinical Use[edit | edit source]
Oritinib is used in the treatment of non-small cell lung cancer (NSCLC) and other cancers that exhibit overexpression or mutations in the EGFR. It is particularly effective in patients whose tumors have specific mutations in the EGFR gene, which make them more susceptible to TKI therapy.
Side Effects[edit | edit source]
Common side effects of oritinib include skin rash, diarrhea, and fatigue. These side effects are generally manageable with supportive care and dose adjustments. More serious side effects can include interstitial lung disease and liver toxicity, which require careful monitoring and management by healthcare professionals.
Development and Approval[edit | edit source]
Oritinib was developed as part of a class of targeted cancer therapies designed to interfere with specific molecular targets involved in tumor growth and progression. Its development involved extensive preclinical and clinical testing to establish its efficacy and safety profile.
Related Pages[edit | edit source]
- Tyrosine kinase inhibitor
- Epidermal growth factor receptor
- Non-small cell lung cancer
- Cancer treatment
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
